

Table S1. Baseline characteristics of T2D patients with and without GLP-1RAs stratified by days of supplies of GLP-1RAs

Variable	GLP-1RAs									
	No	Yes								
		1-59 days		60-153 days		154-251 days		> 251 days		
		n (%) / mean ±	P-value	n (%) / mean ±	P-value	n (%) / mean ±	P-value	n (%) / mean ±	P-value	
		SD	SD	SD	SD	SD	SD	SD	SD	
All	6,534 (50.00)		1,617 (12.37)		1,628 (12.46)		1,583 (12.11)		1,706 (13.05)	
Sex			0.2451		0.1954		0.9208		0.6002	
Female	3,435 (52.57)		824 (50.96)		885 (54.36)		830 (52.43)		909 (53.28)	
Male	3,099 (47.43)		793 (49.04)		743 (45.64)		753 (47.57)		797 (46.72)	
Age group (year)			0.0001		0.0014		0.2753		0.5159	
20-29	322 (4.93)		92 (5.69)		111 (6.82)		74 (4.67)		80 (4.69)	
30-39	1,177 (18.01)		276 (17.07)		333 (20.45)		291 (18.38)		310 (18.17)	
40-49	1,805 (27.62)		418 (25.85)		441 (27.09)		463 (29.25)		495 (29.02)	
50-59	1,914 (29.29)		425 (26.28)		453 (27.83)		473 (29.88)		507 (29.72)	
60 +	1,316 (20.14)		406 (25.11)		290 (17.81)		282 (17.81)		314 (18.41)	
Comorbidities										
Hypertension			0.8520		0.5810		0.1493		0.6330	
No	2,154 (32.97)		537 (33.21)		525 (32.25)		552 (34.87)		552 (32.36)	
Yes	4,380 (67.03)		1,080 (66.79)		1,103 (67.75)		1,031 (65.13)		1,154 (67.64)	
Dyslipidemia			0.0275		0.0747		0.5765		0.5734	
No	861 (13.18)		247 (15.28)		242 (14.86)		217 (13.71)		216 (12.66)	

<i>Yes</i>	5,673 (86.82)	1,370 (84.72)	1,386 (85.14)	1,366 (86.29)	1,490 (87.34)
Smoking		0.3441	0.3725	0.7258	0.6602
<i>No</i>	6,254 (95.71)	1,539 (95.18)	1,550 (95.21)	1,512 (95.51)	1,637 (95.96)
<i>Yes</i>	280 (4.29)	78 (4.82)	78 (4.79)	71 (4.49)	69 (4.04)
Obesity		0.3261	0.0509	0.1724	0.0039
<i>No</i>	5,243 (80.24)	1,315 (81.32)	1,271 (78.07)	1,246 (78.71)	1,315 (77.08)
<i>Yes</i>	1,291 (19.76)	302 (18.68)	357 (21.93)	337 (21.29)	391 (22.92)
Chronic kidney disease		0.0073	0.6285	0.5378	0.5213
<i>No</i>	6,140 (93.97)	1,490 (92.15)	1,535 (94.29)	1,481 (93.56)	1,596 (93.55)
<i>Yes</i>	394 (6.03)	127 (7.85)	93 (5.71)	102 (6.44)	110 (6.45)
Antidiabetic drugs					
Metformin		0.1205	0.8088	0.7706	0.5456
<i>No</i>	14 (0.21)	7 (0.43)	4 (0.25)	4 (0.25)	5 (0.29)
<i>Yes</i>	6,520 (99.79)	1,610 (99.57)	1,624 (99.75)	1,579 (99.75)	1,701 (99.71)
Sulfonylureas		0.0581	0.4338	0.0005	0.1415
<i>No</i>	353 (5.40)	107 (6.62)	96 (5.90)	122 (7.71)	77 (4.51)
<i>Yes</i>	6,181 (94.60)	1,510 (93.38)	1,532 (94.10)	1,461 (92.29)	1,629 (95.49)
DPP-4 i		0.0255	0.6854	0.0057	0.0493
<i>No</i>	767 (11.74)	158 (9.77)	197 (12.10)	226 (14.28)	230 (13.48)
<i>Yes</i>	5,767 (88.26)	1,459 (90.23)	1,431 (87.90)	1,357 (85.72)	1,476 (86.52)
Thiazolidinediones		0.2277	0.1012	0.0049	0.0247
<i>No</i>	2,425 (37.11)	574 (35.50)	640 (39.31)	648 (40.93)	583 (34.17)
<i>Yes</i>	4,109 (62.89)	1,043 (64.50)	988 (60.69)	935 (59.07)	1,123 (65.83)

SGLT-2i			0.0283		<0.000 1		0.0093		<0.000 1
<i>No</i>	3,945 (60.38)	928 (57.39)		866 (53.19)		1,012 (63.93)		1,149 (67.35)	
<i>Yes</i>	2,589 (39.62)	689 (42.61)		762 (46.81)		571 (36.07)		557 (32.65)	
Insulins			<0.000 1		0.0040		<0.000 1		0.0004
<i>No</i>	1,442 (22.07)	253 (15.65)		306 (18.80)		436 (27.54)		446 (26.14)	
<i>Yes</i>	5,092 (77.93)	1,364 (84.35)		1,322 (81.20)		1,147 (72.46)		1,260 (73.86)	
Statins			0.2960		0.0719		0.6101		0.1271
<i>No</i>	1,488 (22.77)	388 (24.00)		405 (24.88)		370 (23.37)		359 (21.04)	
<i>Yes</i>	5,046 (77.23)	1,229 (76.00)		1,223 (75.12)		1,213 (76.63)		1,347 (78.96)	
Antihypertensive agents			0.5387		0.4300		0.3709		0.9610
<i>No</i>	1,252 (19.16)	299 (18.49)		326 (20.02)		319 (20.15)		326 (19.11)	
<i>Yes</i>	5,282 (80.84)	1,318 (81.51)		1,302 (79.98)		1,264 (79.85)		1,380 (80.89)	
Anticoagulants			0.0810		0.4655		0.9787		0.4098
<i>No</i>	6,489 (99.31)	1,599 (98.89)		1,614 (99.14)		1,572 (99.31)		1,691 (99.12)	
<i>Yes</i>	45 (0.69)	18 (1.11)		14 (0.86)		11 (0.69)		15 (0.88)	
Antiplatelets			0.0242		0.1454		0.0683		0.4254
<i>No</i>	5,562 (85.12)	1,340 (82.87)		1,409 (86.55)		1,376 (86.92)		1,439 (84.35)	
<i>Yes</i>	972 (14.88)	277 (17.13)		219 (13.45)		207 (13.08)		267 (15.65)	
Follow-up time	3.47 ± 1.95	3.51 ± 1.82	0.4397	3.74 ± 1.85	<0.000 1	2.97 ± 1.94	<0.000 1	3.78 ± 2.11	<0.000 1
Outpatient visit for T2DM	24.46 ± 19.97	26.71 ± 20.99	<0.000	27.81 ± 21.33	<0.000	21.99 ± 19.13	<0.000	30.73 ± 21.93	<0.000

			1		1		1		1
GLP-1RAs prescription refill record	-	1.65 ± 1.91	NA	4.11 ± 1.94	NA	7.15 ± 1.16	NA	14.19 ± 7.19	NA
Compliance rate for GLP-1RAs	-	11.15 ± 14.62	NA	26.33 ± 28.91	NA	57.44 ± 42.41	NA	65.10 ± 73.75	NA

All GLP-1RAs users in each group of days' supplies of GLP-1RAs were compared with GLP-1RAs non-users.

Abbreviation: DDP-4i, Dipeptidyl Peptidase 4 inhibitors; GLP-1RAs, Glucagon Like Peptide-1 Receptor Agonists; SD, Standard Deviation; SGLT2i, Sodium-Glucose coTransporter 2 inhibitor; T2D, Type 2 Diabetes.